OncoMatch/Clinical Trials/NCT06184750
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Is NCT06184750 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Tamoxifen for breast atypical ductal hyperplasia.
Treatment: Tamoxifen — This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well established risk factor for breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen has been shown to reduce breast density, even at reduced dosages, and is approved for the prevention of breast cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 expression
history of unilateral estrogen receptor (ER) positive ductal carcinoma in situ (DCIS)
Excluded: BRCA1 mutation
Women with known gene mutations associated with an increased risk for breast cancer such as BRCA1/2, CDH1, PALB2, PTEN, STK11, or P53
Excluded: BRCA2 mutation
Women with known gene mutations associated with an increased risk for breast cancer such as BRCA1/2, CDH1, PALB2, PTEN, STK11, or P53
Excluded: CDH1 mutation
Women with known gene mutations associated with an increased risk for breast cancer such as BRCA1/2, CDH1, PALB2, PTEN, STK11, or P53
Excluded: PALB2 mutation
Women with known gene mutations associated with an increased risk for breast cancer such as BRCA1/2, CDH1, PALB2, PTEN, STK11, or P53
Excluded: PTEN mutation
Women with known gene mutations associated with an increased risk for breast cancer such as BRCA1/2, CDH1, PALB2, PTEN, STK11, or P53
Excluded: STK11 mutation
Women with known gene mutations associated with an increased risk for breast cancer such as BRCA1/2, CDH1, PALB2, PTEN, STK11, or P53
Excluded: TP53 mutation
Women with known gene mutations associated with an increased risk for breast cancer such as BRCA1/2, CDH1, PALB2, PTEN, STK11, or P53
Disease stage
Excluded: Stage INVASIVE BREAST CANCER, PRIOR INVASIVE CANCER ≥ T1 (OTHER THAN NON-MELANOMA SKIN CANCER), UNLESS CURATIVELY TREATED, AND ALL TREATMENT WAS COMPLETED > 5 YEARS PRIOR TO ENROLLMENT
History of invasive breast cancer; Prior invasive cancer ≥ T1 (other than non-melanoma skin cancer), unless curatively treated, and all treatment was completed > 5 years prior to enrollment
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arizona Cancer Center - Prevention Research Clinic · Tucson, Arizona
- Northwestern University · Chicago, Illinois
- University of Illinois College of Medicine - Chicago · Chicago, Illinois
- University of Kansas Cancer Center · Kansas City, Kansas
- Brigham and Women's Hospital · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06184750 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ESR1?
Yes, ESR1 expression is a required biomarker for enrollment.
Are patients with BRCA1 alterations eligible?
No. BRCA1 mutation is an exclusion criterion.
Are patients with BRCA2 alterations eligible?
No. BRCA2 mutation is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 55 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages